349553-98-6
349553-98-6
Chemical Structure
DL-Mevalonolactone-d4
Synonym(s): (±)-Mevalonolactone-d4; Mevalolactone-d4
- CAS No.: 349553-98-6
- Formula:C6H6D4O3
- Molecular Weight:134.17
IUPAC Name: 4-hydroxy-4-methyltetrahydro-2H-pyran-2-one-5,5,6,6-d4
InChIKey: JYVXNLLUYHCIIH-RRVWJQJTSA-N
SMILES: OC(C)(C1)C([2H])(C([2H])(OC1=O)[2H])[2H]
Biological Activity: DL-Mevalonolactone-d4 ( (±)-Mevalonolactone-d4) is the deuterium labeled DL-Mevalonolactone (HY-107855). DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy[3]. DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling[2][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
DL-Mevalonolactone-d4 | DL-Mevalonolactone-d4 ( (±)-Mevalonolactone-d4) is the deuterium labeled DL-Mevalonolactone (HY-107855). DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy. DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DL-Mevalonolactone (Standard) | ≥98% | DL-Mevalonolactone (Standard) is the analytical standard of DL-Mevalonolactone. This product is intended for research and analytical applications. DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy. DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DL-Mevalonolactone-13C2 | DL-Mevalonolactone-13C2 ((±)-Mevalonolactone-13C2) is the 13C-labeled DL-Mevalonolactone (HY-107855). DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy. DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DL-Mevalonolactone-13C | DL-Mevalonolactone-13C ((±)-Mevalonolactone-13C) is the 13C-labeled DL-Mevalonolactone (HY-107855). DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy. DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DL-Mevalonolactone-d7 | 99.27% | DL-Mevalonolactone-d7 is the deuterium labeled DL-Mevalonolactone. DL-Mevalonolactone ((±)-Mevalonolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone (Mevalonolactone) decreases mitochondrial membrane potential (?Ψm), NAD(P)H content and the capacity to retain Ca2+ in the brain, besides inducing mitochondrial swelling. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DL-Mevalonolactone-d3 | DL-Mevalonolactone-d3 is the deuterium labeled DL-Mevalonolactone. DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone (Mevalonolactone) decreases mitochondrial membrane potential ( Ψm), NAD(P)H content and the capacity to retain Ca2+ in the brain, besides inducing mitochondrial swelling. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DL-Mevalonolactone | 99.15% | DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy. DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [2]. Cecatto C, et al. Mevalonolactone disrupts mitochondrial functions and induces permeability transition pore opening in rat brain mitochondria: Implications for the pathogenesis of mevalonic aciduria. Neurochem Int. 2017 Sep;108:133-145. [Content Brief]
- [3]. Yogev Y, et al., Limb girdle muscular disease caused by HMGCR mutation and statin myopathy treatable with mevalonolactone. Proc Natl Acad Sci U S A. 2023 Feb 14;120(7):e2217831120. [Content Brief]
- [4]. Gratton R, et al., Prolonged treatment with mevalonolactone induces oxidative stress response with reactive oxygen species production, mitochondrial depolarization and inflammation in human glioblastoma U-87 MG cells. Neurochem Int. 2018 Nov;120:233-237. [Content Brief]
